



August 9, 2010

## Stock-of-the-Week: Burcon NutraScience Corporation (TSX: BU)

### Quick Facts

#### One Year Chart (BU)



Source: [www.bigcharts.com](http://www.bigcharts.com)

**Price (Aug. 6/10):**

**\$8.25**

**52-Week High-Low:**

**\$10.60 - \$6.31**

**Average Daily Volume:**

**50-day: 13,700**

**200-day: 25,100**

**Shares Outstanding:**

**29.1 million**

**Market Capitalization:**

**\$240.1 billion**

**Year-End:**

**March 31**

**Symbol: TSX: BU**

**Website: [www.burcon.ca](http://www.burcon.ca)**

### Viewpoint

Burcon NutraScience Corporation is a research and development company developing plant protein extraction and purification technology. The Company has built a significant patent portfolio and currently has 127 issued patents in various countries and over 200 additional patent pending applications, 65 of which are U.S. patent applications.

Burcon's research is focused on the world's first commercial canola proteins, Puratein and Supertein, which have important functional and nutritional attributes, and CLARISOY, a soy protein isolate which is 100% soluble and transparent in acidic solutions.

Puratein is primarily suited for emulsifying, thickening, gelling, binding, aeration, and nutrition. Markets for this product include dressings and sauces, meat substitutes, and baked goods such as protein bars. Supertein is a highly soluble product which is attractive for transparency and foaming. It can be used for beverages, confectionery and aerated desserts.

Burcon expects to form an alliance with one or more companies to commercialize its CLARISOY soy protein isolate, which is initially targeted at the food and beverage industry. Its advantages over other soy products are its good flavour characteristics as well as 100% solubility and transparency.

In September 2003, the Company signed a licence and development agreement with Archer Daniels Midland, to aid in the development, production and marketing of the canola-based isolates on a worldwide basis. By October 2008, the Company had achieved self-affirmed "GRAS" (Generally Regarded as Safe) status for its canola-based isolates for food and beverage applications in the U.S.A. In April 2010, the U.S. Food and Drug Administration (FDA) advised Burcon that its application had been received. The Company is currently awaiting FDA approval, which may take up to 180 days.

Burcon is also pursuing approval of Puratein and Supertein as "novel foods" from the Food Directorate, Health Products and Food Branch of Health Canada, and in Europe. Approval in Canada and Europe could take between a year and a half and two and a half years.

*Bob Weir, B.Sc./B.Comm./CFA and Managing Director, Research Services*